SCD

TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders
Κλινικά Νέα

TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders

A key objective of the Thalassaemia International Federation is to inform and update regularly the global haemoglobinopathies family, both patients and physicians, on the progress and new developments that arise…
UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease
Κλινικά Νέα

UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease

For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK National Health Service (NHS). Crizanlizumab (Adakveo) by Novartis…
Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years
Κλινικά Νέα

Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years

Children with sickle cell disease (SCD) as young as age 4 could be prescribed Oxbryta (Voxelotor) if the U.S. Food and Drug Administration (FDA) approves a supplemental new drug application (sNDA) submitted by…
Adakveo (Crizanlizumab)
Clinical Trial Updates (SCD)

Adakveo (Crizanlizumab)

  Update: 27 October 2021 The National Institute for Health and Care Excellence (NICE) has published the Final Appraisal Determination (FAD) recommending Adakveo as an option for preventing recurrent sickle…
Oxbryta (Voxelotor)
Clinical Trial Updates (SCD)

Oxbryta (Voxelotor)

Update: 27 October 2021 The U.S. Food and Drug Administration (FDA) has agreed to consider Global Blood Therapeutics’ (GBT) request to expand the use of Oxbryta (voxelotor) to children as…
Clinical Trials Update: The June 2021 Edition
Κλινικά Νέα

Clinical Trials Update: The June 2021 Edition

TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
TIF Is Actively Participating In The 26th EHA Annual Congress
Κλινικά Νέα

TIF Is Actively Participating In The 26th EHA Annual Congress

TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17 June 2021. Ms Lily Cannon, TIF Operations Manager, attended a…
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies
Κλινικά Νέα

Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies

bluebird bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin…
Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD
Κλινικά Νέα

Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD

Global Blood Therapeutics, Inc. announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease…
TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April
Νέα

TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April

TIF is delighted to announce the organisation of a Virtual Presentation Event of the ‘TIF Sickle Cell Disease Educational Course for Healthcare Professionals’ – an online course providing comprehensive information…
Back to top button